Skip to main content

Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development

PURCHASE, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), announced the appointment of Paul J. Tiseo, Ph.D. to the newly created role of vice president of clinical development. Dr. Tiseo brings to Cognition more than two decades of strategic and operational expertise leading the clinical development of central nervous system (CNS) drug candidates, including Aricept® and Namenda®.

“We are now enrolling participants in three clinical studies: two for mild-to-moderate Alzheimer’s disease and one for dementia with Lewy bodies with plans to commence enrollment in studies for early Alzheimer’s disease and dry age-related macular degeneration in the near-term," stated Lisa Ricciardi, Cognition’s president and CEO. “Paul will bring important skills to our clinical development team and add a level of oversight and strategic direction that will put us on a strong footing for our future clinical efforts.”

Dr. Tiseo was most recently the executive director of clinical development at Centrexion Therapeutics, a private biotechnology company focused on the development of non-opioid drugs for the treatment of acute and chronic pain. At Centrexion he worked with the clinical operations and regulatory teams to develop and execute strategies for the clinical development of the company’s lead Phase 3 candidate as well as a pipeline of earlier stage therapeutics. Previously Dr. Tiseo was the clinical lead for pain therapeutics at Regeneron, working to develop the anti-nerve growth factor monoclonal antibody, fasinumab for the treatment of osteoarthritis pain. In this position he worked within a multidisciplinary team to craft clinical strategy and study protocols, prepare global regulatory submissions, and liaise with pharmaceutical partners on joint development committees. Earlier in his career he was a medical team leader at Pfizer and served in various clinical development capacities at Forest Laboratories and Eisai.

Dr. Tiseo earned a Bachelor of Science from Stony Brook University and a Doctor of Philosophy in pharmacology from the Temple University Lewis Katz School of Medicine. He completed postgraduate training in the Neurology Pain Service at Memorial Sloan Kettering and conducted research in pain and analgesic mechanisms in the Department of Anesthesiology at UC San Diego. He is author or co-author of over 30 peer-reviewed journal articles summarizing clinical results and is named on a seminal patents covering the use of cholinesterase inhibitors and antibodies against nerve growth factor.

Dr. Tiseo added, “The number and scope of ongoing clinical studies and the potential that resides in the Cognition Therapeutics pipeline presented a compelling opportunity for me. I’m looking forward to joining the team of medical, chemistry and clinical professionals at Cognition to enhance the development strategies in place so that we can continue to advance CT1812 to near-term data readouts and subsequently to registrational studies.”

About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our cash and financial resources and our clinical development plans, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition, our ability to secure new (and retain existing) grant funding, our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto (including with respect to patient recruitment efforts); the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; issues related to supply chain and the labor force; and the risks and uncertainties described in the “Risk Factors” section of our filings made with the Securities Exchange Commission. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact Information: 
Cognition Therapeutics, Inc.

Aline Sherwood (media) 
Scienta Communications

Daniel Kontoh-Boateng/Rosalyn Christian (investors) 
Tiberend Strategic Advisors, Inc.

Primary Logo

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.